Soleus Capital Master Fund, L.P. is 10% Owner at Lyra Therapeutics, Inc. (LYRA). They have made 2 open-market trades across 1 company since 2020, most recently 2020-05-05.
CIK 0001812275
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $2.5M since 2020, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LYRA | 338,330 | $167K |
Shares reported on the most recent Form 4, priced at the 2020-05-15 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.